Prostate Cancer ADT Increases Bone Fracture Risk
Investigators examined the risk of bone fracture associated with different forms of androgen deprivation therapy.
Investigators examined the risk of bone fracture associated with different forms of androgen deprivation therapy.
Statin use in prostate cancer is attractive given their proven cardiovascular benefits and favorable toxicity profile, according to investigators.
Latest findings are from a post hoc analysis of the phase 3 VISION trial.
The sNDA is supported by data from the phase 3 PROpel trial which included adults with mCRPC in the first-line setting.
The approval was based on data from the phase 3 ARASENS trial.
The LEAP-002 study evaluated pembrolizumab plus lenvatinib in patients with uHCC; the KEYNOTE-921 study evaluated pembrolizumab plus docetaxel in patients with mCRPC.
A report in the Journal of the National Cancer Institute presents findings from the first assessment of the real-world safety of abiraterone and enzalutamide in a national sample of Medicare beneficiaries with advanced prostate cancer.
Stay up-to-date on the latest drugs in development.
The sNDA is supported by data from the phase 3 ARASENS trial, which included1306 patients with mHSPC.
Camcevi is a ready-to-use 6-month subcutaneous depot formulation of leuprolide mesylate, a gonadotropin-releasing hormone agonist.